Enfuvirtide administration in HIV-positive transgender patient with soft tissue augmentation: US evaluation.
Enfuvirtide is a large protein that should be injected subcutaneously to ensure an appropriate absorption. Here we report the case of a transgender HIV-positive patient receiving enfuvirtide with an individualized background regimen of antiretroviral drugs, who had previously undergone liquid silicone oil injections. We performed US scan to detect silicone-free areas for following enfuvirtide injections. US can be useful in the correct management of those patients with liquid silicone oil soft tissue augmentation who require subcutaneously injected drugs.
Gabrielli
Eugenia
E
Clinical Science Department, Section of Infectious Diseases, University of Milan, L. Sacco Hospital, Milan, Italy.
Ferraioli
Giovanna
G
Ferraris
Laurenzia
L
Riva
Agostino
A
Galli
Massimo
M
Filice
Carlo
C
Gervasoni
Cristina
C
D000328:Adult; D019380:Anti-HIV Agents / Q000008:administration & dosage*; D018427:Breast Implants / Q000009:adverse effects; D000077560:Enfuvirtide; D015700:HIV Envelope Protein gp41 / Q000008:administration & dosage*; D015658:HIV Infections / Q000000981:diagnostic imaging* / Q000188:drug therapy*; D006801:Humans; D008297:Male; D010446:Peptide Fragments / Q000008:administration & dosage*; D012827:Silicone Oils / Q000009:adverse effects; D040521:Subcutaneous Tissue / Q000000981:diagnostic imaging*; D014189:Transsexualism / Q000000981:diagnostic imaging*; D014463:Ultrasonography
D019380:Anti-HIV Agents; D015700:HIV Envelope Protein gp41; D010446:Peptide Fragments; D012827:Silicone Oils; D000077560:Enfuvirtide